Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis
<h3>Introduction</h3><p dir="ltr">Acute myeloid leukemia (AML) is a significant hematological malignancy in the United States, with a high mortality rate and limited treatment options. CAR T-cell therapy, a new and promising treatment, is being investigated for its effica...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513516039307264 |
|---|---|
| author | Mahmoud M. Morsy (18560491) |
| author2 | Ahmed Y. Azzam (14267391) Osman Elamin (18560494) Adam Elswedy (18560497) Abdulqadir J. Nashwan (11659453) |
| author2_role | author author author author |
| author_facet | Mahmoud M. Morsy (18560491) Ahmed Y. Azzam (14267391) Osman Elamin (18560494) Adam Elswedy (18560497) Abdulqadir J. Nashwan (11659453) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mahmoud M. Morsy (18560491) Ahmed Y. Azzam (14267391) Osman Elamin (18560494) Adam Elswedy (18560497) Abdulqadir J. Nashwan (11659453) |
| dc.date.none.fl_str_mv | 2024-05-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.leukres.2024.107498 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Safety_and_efficacy_of_chimeric_antigen_receptor_T-cell_therapy_for_acute_myeloid_leukemia_A_subgroup_based_meta-analysis/25826917 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Oncology and carcinogenesis Acute myeloid leukemia CAR-T cell therapy Hematology Oncology |
| dc.title.none.fl_str_mv | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Introduction</h3><p dir="ltr">Acute myeloid leukemia (AML) is a significant hematological malignancy in the United States, with a high mortality rate and limited treatment options. CAR T-cell therapy, a new and promising treatment, is being investigated for its efficacy and safety in AML. This meta-analysis aims to assess the safety and efficacy of CAR T-cell therapy in AML, considering various subgroups such as study location, study design, prior transplantation status, conditioning regimen, and CAR T-cell source.</p><p><br></p><h3>Methods</h3><p dir="ltr">We conducted a comprehensive literature review across multiple databases, adhering to PRISMA guidelines and focusing on studies concerning CAR T-cell therapy in AML. We included original articles in English and excluded non-original reviews, abstracts, and non-English studies. The risk of bias was assessed using the Cochrane ROBINS-I tool. Statistical analysis involved meta-analysis with Cochrane’s Q-test and I² statistic, using both fixed-effect and random-effects models, and assessed for publication bias.</p><p><br></p><h3>Results</h3><p dir="ltr">Our search yielded studies encompassing 57 AML patients treated with CAR T-cell therapy. The meta-analysis revealed a 48% incidence of complete remission with CAR T-cell therapy, varying significantly across subgroups based on study design, location, prior transplantation, conditioning regimen, and CAR T-cell source. The highest complete remission rates were observed in patients from China, those who had undergone prior hematopoietic cell transplantation, and those treated with fludarabine and cyclophosphamide conditioning regimen. Adverse events included graft-versus-host disease (7%) and cytokine release syndrome (53%).</p><p><br></p><h3>Conclusions</h3><p dir="ltr">This meta-analysis highlights the potential of CAR T-cell therapy in AML treatment, especially when integrated with certain prior treatments and conditioning regimens. The findings suggest a higher efficacy in patients with previous hematopoietic cell transplantation and specific conditioning regimens. Further large-scale, randomized trials are essential to confirm these findings and establish CAR T-cell therapy as a standard treatment for AML.</p><h2>Other Information</h2><p dir="ltr">Published in: Leukemia Research<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.leukres.2024.107498" target="_blank">https://dx.doi.org/10.1016/j.leukres.2024.107498</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a62e72b7d356b8ff088ac1fa6aef9815 |
| identifier_str_mv | 10.1016/j.leukres.2024.107498 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25826917 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysisMahmoud M. Morsy (18560491)Ahmed Y. Azzam (14267391)Osman Elamin (18560494)Adam Elswedy (18560497)Abdulqadir J. Nashwan (11659453)Biomedical and clinical sciencesOncology and carcinogenesisAcute myeloid leukemiaCAR-T cell therapyHematologyOncology<h3>Introduction</h3><p dir="ltr">Acute myeloid leukemia (AML) is a significant hematological malignancy in the United States, with a high mortality rate and limited treatment options. CAR T-cell therapy, a new and promising treatment, is being investigated for its efficacy and safety in AML. This meta-analysis aims to assess the safety and efficacy of CAR T-cell therapy in AML, considering various subgroups such as study location, study design, prior transplantation status, conditioning regimen, and CAR T-cell source.</p><p><br></p><h3>Methods</h3><p dir="ltr">We conducted a comprehensive literature review across multiple databases, adhering to PRISMA guidelines and focusing on studies concerning CAR T-cell therapy in AML. We included original articles in English and excluded non-original reviews, abstracts, and non-English studies. The risk of bias was assessed using the Cochrane ROBINS-I tool. Statistical analysis involved meta-analysis with Cochrane’s Q-test and I² statistic, using both fixed-effect and random-effects models, and assessed for publication bias.</p><p><br></p><h3>Results</h3><p dir="ltr">Our search yielded studies encompassing 57 AML patients treated with CAR T-cell therapy. The meta-analysis revealed a 48% incidence of complete remission with CAR T-cell therapy, varying significantly across subgroups based on study design, location, prior transplantation, conditioning regimen, and CAR T-cell source. The highest complete remission rates were observed in patients from China, those who had undergone prior hematopoietic cell transplantation, and those treated with fludarabine and cyclophosphamide conditioning regimen. Adverse events included graft-versus-host disease (7%) and cytokine release syndrome (53%).</p><p><br></p><h3>Conclusions</h3><p dir="ltr">This meta-analysis highlights the potential of CAR T-cell therapy in AML treatment, especially when integrated with certain prior treatments and conditioning regimens. The findings suggest a higher efficacy in patients with previous hematopoietic cell transplantation and specific conditioning regimens. Further large-scale, randomized trials are essential to confirm these findings and establish CAR T-cell therapy as a standard treatment for AML.</p><h2>Other Information</h2><p dir="ltr">Published in: Leukemia Research<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.leukres.2024.107498" target="_blank">https://dx.doi.org/10.1016/j.leukres.2024.107498</a></p>2024-05-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.leukres.2024.107498https://figshare.com/articles/journal_contribution/Safety_and_efficacy_of_chimeric_antigen_receptor_T-cell_therapy_for_acute_myeloid_leukemia_A_subgroup_based_meta-analysis/25826917CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/258269172024-05-01T00:00:00Z |
| spellingShingle | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis Mahmoud M. Morsy (18560491) Biomedical and clinical sciences Oncology and carcinogenesis Acute myeloid leukemia CAR-T cell therapy Hematology Oncology |
| status_str | publishedVersion |
| title | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis |
| title_full | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis |
| title_fullStr | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis |
| title_full_unstemmed | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis |
| title_short | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis |
| title_sort | Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis |
| topic | Biomedical and clinical sciences Oncology and carcinogenesis Acute myeloid leukemia CAR-T cell therapy Hematology Oncology |